Speaker: Michael Mourez, Head BacteriOmics Platform, Evotec, France
Moderator: Laura Piddock, Director Scientific Affairs, GARDP
In this webinar, the following aspects were presented:
- What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?
- What are some techniques that may be used to understand the origins of resistance selection?
- How to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?
The presentation was followed by a Q&A session.
* This presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’, jointly organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019 *
This live webinar including interactive Q&A session was broadcast on 21 January 2020.
If you have questions or comments, please let us know. Do so by submitting them via the ‘Talk to an expert’ feature or contact us per email: email@example.com.